ACDC (medicine)
Rare genetic disorder causing arterial and joint calcification
Arterial calcification due to deficiency of CD73 | |
---|---|
Synonyms | ACDC, CD73 deficiency |
Pronounce | N/A |
Specialty | N/A |
Symptoms | Arterial calcification, joint stiffness, chronic pain |
Complications | Peripheral artery disease, claudication, mobility impairments |
Onset | Typically early to mid-adulthood |
Duration | Lifelong |
Types | |
Causes | Mutation in the NT5E gene |
Risks | Family history, genetic predisposition |
Diagnosis | Genetic testing, radiographic imaging |
Differential diagnosis | Pseudoxanthoma elasticum, vascular calcification, arteriosclerosis |
Prevention | None |
Treatment | Symptomatic; investigational use of adenosine or phosphatase inhibitors |
Medication | Experimental therapies |
Prognosis | Progressive, but not typically life-threatening |
Frequency | Extremely rare |
Deaths | Rare, related to cardiovascular complications |
Arterial calcification due to deficiency of CD73 (ACDC) is a rare genetic disorder characterized by abnormal calcium deposits in the arteries and joints, especially in the lower limbs. The condition results from mutations in the NT5E gene, which encodes the CD73 enzyme that plays a crucial role in purine metabolism and the regulation of vascular calcification.
History[edit | edit source]
Although patients with symptoms consistent with ACDC were first documented as early as 1914, the disorder remained poorly understood for nearly a century. It was not until 2011 that researchers were able to pinpoint the exact genetic cause: mutations in the NT5E gene that lead to a deficiency of CD73 enzyme activity.
Genetics[edit | edit source]
ACDC is caused by autosomal recessive mutations in the NT5E gene located on chromosome 6. This gene encodes the CD73 enzyme, which is involved in converting adenosine monophosphate (AMP) to adenosine. In individuals with ACDC, the deficiency in CD73 leads to a reduction in adenosine production, which normally plays a role in inhibiting vascular and soft tissue calcification.
Pathophysiology[edit | edit source]
In the absence of CD73 function, the molecular pathways that prevent calcium phosphate deposition in the vasculature are impaired. This results in progressive calcification of medium- and small-sized arteries and periarticular tissues, particularly in the hands, feet, and lower extremities.
Clinical presentation[edit | edit source]
The main symptoms of ACDC include:
- Progressive calcification of arteries and joints
- Claudication (pain during walking)
- Chronic pain in the lower limbs
- Joint stiffness and reduced range of motion
- In some cases, vascular insufficiency or peripheral artery disease
Diagnosis[edit | edit source]
ACDC diagnosis is confirmed by:
- Clinical evaluation of symptoms
- Imaging studies such as X-rays, CT scans, or MRI that reveal calcified arteries and joints
- Genetic testing to identify mutations in the NT5E gene
Treatment[edit | edit source]
There is currently no cure for ACDC. Treatment is symptomatic and may include:
- Pain management using analgesics
- Surgical intervention to remove calcified deposits or improve blood flow
- Physical therapy to preserve mobility and reduce stiffness
Experimental therapies[edit | edit source]
Recent molecular studies have demonstrated that treatment with adenosine or phosphatase inhibitors in laboratory models may reverse or prevent calcification associated with CD73 deficiency. These findings are preliminary but offer hope for future therapeutic development.
Prognosis[edit | edit source]
ACDC is a progressive condition that can significantly impact quality of life, particularly due to pain and reduced mobility. However, it is generally not life-threatening unless significant vascular complications develop.
Epidemiology[edit | edit source]
ACDC is an extremely rare disorder, with fewer than 20 families described in medical literature as of the 2020s. The true prevalence is unknown due to underdiagnosis and lack of awareness.
See also[edit | edit source]
External links[edit | edit source]
NIH genetic and rare disease info[edit source]
ACDC (medicine) is a rare disease.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD